{
    "clinical_study": {
        "@rank": "15003", 
        "arm_group": [
            {
                "arm_group_label": "ESWT (Extracorporal Shock Wave Therapy)", 
                "arm_group_type": "Other", 
                "description": "Three applications in weekly interval."
            }, 
            {
                "arm_group_label": "hyaluronic acid sodium salt", 
                "arm_group_type": "Active Comparator", 
                "description": "Two injections of 2% (40 milligrams (mg) / 2 millilitres (ml)) hyaluronan in weekly interval."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to compare OSTENIL\u00ae TENDON (2% hyaluronan) and\n      Extracorporeal Shock Wave (ESWT) therapy in the treatment of painful Achilles tendinopathy."
        }, 
        "brief_title": "Hyaluronan in the Treatment of Painful Achilles Tendinopathy.", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Tendinopathy", 
        "condition_browse": {
            "mesh_term": "Tendinopathy"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female patients between 18 and 75 years of age.\n\n          -  Good general health condition.\n\n          -  Signed written informed consent.\n\n          -  Painful Achilles midportion tendinopathy since more or equal than 6 weeks.\n\n          -  Pain according to VAS (Huskisson, 100 mm) more or equal than 40 mm.\n\n          -  Ensured compliance of subjects over the whole study period.\n\n        Exclusion Criteria:\n\n          -  Concomitant or previous participation in a clinical investigation within the last 3\n             months prior to study inclusion.\n\n          -  Infection or relevant skin disease at study relevant site.\n\n          -  Blood coagulation disorder or intake of blood thinner (e.g. Marcumar).\n\n          -  Known hypersensitivity to hyaluronic acid (HA) preparations or to the constituents\n             mannitol, sodium chloride, disodium phosphate and sodium dihydrogenphosphate.\n\n          -  Contra-indications for ESWT application in study relevant area (e.g. recent surgery,\n             malignant tumour, local osteomyelitis or open epiphysis).\n\n          -  Severe intercurrent illness (e.g. uncontrolled diabetes mellitus, peripheral\n             neuropathy), which in the opinion of the investigator, may put the patient at risk\n             when participating in the study, or affect the patient's ability to take part in the\n             study.\n\n          -  Concomitant disease at study relevant site (e.g. insertion tendinopathy at Achilles\n             tendon) influencing study evaluation.\n\n          -  Diseases or characteristics judged by the investigator to be incompatible with the\n             assessments and/or procedures for the study evaluation.\n\n          -  Intake of concomitant medications not allowed which might interfere with the\n             functional assessment of the study (e.g. immunosuppressive drugs within the last 3\n             months).\n\n          -  Previous therapies (except non-steroidal anti-inflammatory drugs (NSAID)) at study\n             relevant site within the last 4 weeks prior to study inclusion.\n\n          -  Use of NSAIDs within the last week prior to study treatment.\n\n          -  Recent history of drug and/or alcohol abuse (within the last 6 months).\n\n          -  Pregnant or lactating females.\n\n          -  Participants of childbearing age (pre-menopausal) who do not accept the use of\n             methods of birth control with pearl index of at least 1 (i.e. oral contraceptives,\n             vaginal ring, hormone-releasing Intrauterine Device (IUD), implants, depot syringes,\n             hormone patch, double barrier method, tubal ligation, vasectomised partner,\u2026) during\n             the treatment period and the first 4 weeks of follow-up period.\n\n          -  Subjects not capable of contracting and of understanding the nature, risks,\n             significance and implications of the clinical investigation and unable to form a\n             rational intention in the light of these facts.\n\n          -  Subjects unable to understand informed consent or having a high probability of non\n             compliance to the study procedures and / or non completion of the study according to\n             investigator's judgement (e.g. illiteracy, insufficient knowledge of local language)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01954108", 
            "org_study_id": "OTENA-INT-2013-03", 
            "secondary_id": "CIV-13-07-011543"
        }, 
        "intervention": [
            {
                "arm_group_label": "hyaluronic acid sodium salt", 
                "intervention_name": "hyaluronic acid sodium salt", 
                "intervention_type": "Device", 
                "other_name": "OSTENIL\u00ae TENDON"
            }, 
            {
                "arm_group_label": "ESWT (Extracorporal Shock Wave Therapy)", 
                "intervention_name": "ESWT", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Hyaluronic Acid"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "tendinopathy", 
            "hyaluronan", 
            "tendon", 
            "hyaluronic acid", 
            "extracorporeal shock wave"
        ], 
        "lastchanged_date": "December 4, 2013", 
        "location": [
            {
                "contact": {
                    "email": "Thierry.DeVroey@uza.be", 
                    "last_name": "Thierry De Vroey, Dr.", 
                    "phone": "+32 (0)3 / 82 13 196"
                }, 
                "contact_backup": {
                    "email": "gaetane.stassijns@uza.be", 
                    "last_name": "Ga\u00ebtane Stassijns, Prof. Dr.", 
                    "phone": "+32 (0)3 / 82 13 983"
                }, 
                "facility": {
                    "address": {
                        "city": "Edegem", 
                        "country": "Belgium", 
                        "zip": "2650"
                    }, 
                    "name": "Universitair Ziekenhuis Antwerpen, Fysische Geneeskunde en Revalidatie"
                }, 
                "investigator": [
                    {
                        "last_name": "Thierry De Vroey, Dr.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Ga\u00ebtane Stassijns, Prof. Dr.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "n.lynen@exinmo.de", 
                    "last_name": "Nils Lynen, Dr.", 
                    "phone": "+49 241-30 20 10"
                }, 
                "contact_backup": {
                    "last_name": "Imke Spiegel, Dr.", 
                    "phone": "+49 241-30 20 10"
                }, 
                "facility": {
                    "address": {
                        "city": "Aachen", 
                        "country": "Germany", 
                        "state": "Nordrhein-Westfalen", 
                        "zip": "52062"
                    }, 
                    "name": "Praxiszentrum Orthop\u00e4die-Unfallchirurgie Nordrhein"
                }, 
                "investigator": [
                    {
                        "last_name": "Nils Lynen, Dr.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Imke Spiegel, Dr.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Germany"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Hyaluronan in the Treatment of Painful Achilles Tendinopathy.", 
        "overall_contact": {
            "email": "dobner@trbchemedica.de", 
            "last_name": "Petra Dobner, Dr.", 
            "phone": "+49 89-46 14 83 20"
        }, 
        "overall_contact_backup": {
            "email": "geiger@trbchemedica.de", 
            "last_name": "Raphaela Geiger", 
            "phone": "+49 89-46 14 83 27"
        }, 
        "overall_official": [
            {
                "affiliation": "Universitair Ziekenhuis Antwerpen, Fysische Geneeskunde en Revalidatie", 
                "last_name": "Thierry De Vroey, Dr. med.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Praxiszentrum Orthop\u00e4die-Unfallchirurgie Nordrhein", 
                "last_name": "Nils Lynen, Dr. med.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The validated questionnaire will be used to evaluate the outcome in Achilles tendinopathy. The score ranges from '0' to '100' whereas '0' denotes 'no activity / maximum pain' and '100' denote 'maximum activity / no pain'.", 
            "measure": "Victorian Institute of Sports Assessment-Achilles (VISA-A score)", 
            "safety_issue": "No", 
            "time_frame": "Day 90 (plus or minus 3 days)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01954108"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The validated questionnaire will be used to evaluate the outcome in Achilles tendinopathy. The score ranges from '0' to '100' whereas '0' denotes 'no activity / maximum pain' and '100' denote 'maximum activity / no pain'.", 
                "measure": "Victorian Institute of Sports Assessment-Achilles (VISA-A score)", 
                "safety_issue": "No", 
                "time_frame": "Day 0"
            }, 
            {
                "description": "The validated questionnaire will be used to evaluate the outcome in Achilles tendinopathy. The score ranges from '0' to '100' whereas '0' denotes 'no activity / maximum pain' and '100' denote 'maximum activity / no pain'.", 
                "measure": "Victorian Institute of Sports Assessment-Achilles (VISA-A score)", 
                "safety_issue": "No", 
                "time_frame": "Day 7 (plus or minus 1 day)"
            }, 
            {
                "description": "The validated questionnaire will be used to evaluate the outcome in Achilles tendinopathy. The score ranges from '0' to '100' whereas '0' denotes 'no activity / maximum pain' and '100' denote 'maximum activity / no pain'.", 
                "measure": "Victorian Institute of Sports Assessment-Achilles (VISA-A score)", 
                "safety_issue": "No", 
                "time_frame": "Day 28 (plus or minus 3 days)"
            }, 
            {
                "description": "The validated questionnaire will be used to evaluate the outcome in Achilles tendinopathy. The score ranges from '0' to '100' whereas '0' denotes 'no activity / maximum pain' and '100' denote 'maximum activity / no pain'.", 
                "measure": "Victorian Institute of Sports Assessment-Achilles (VISA-A score)", 
                "safety_issue": "No", 
                "time_frame": "Day 180 (plus or minus 3 days)"
            }, 
            {
                "description": "Intensity of pain will be evaluated on the Huskisson VAS pain scale on which 0 mm indicate 'no pain' and 100 mm indicate 'extreme pain'.", 
                "measure": "Visual Analogue Scale of pain (VAS; 100 mm)", 
                "safety_issue": "No", 
                "time_frame": "Day 0"
            }, 
            {
                "description": "Intensity of pain will be evaluated on the Huskisson VAS pain scale on which 0 mm indicate 'no pain' and 100 mm indicate 'extreme pain'.", 
                "measure": "Visual Analogue Scale of pain (VAS; 100 mm)", 
                "safety_issue": "No", 
                "time_frame": "Day 7 (plus or minus 1 day)"
            }, 
            {
                "description": "Intensity of pain will be evaluated on the Huskisson VAS pain scale on which 0 mm indicate 'no pain' and 100 mm indicate 'extreme pain'.", 
                "measure": "Visual Analogue Scale of pain (VAS; 100 mm)", 
                "safety_issue": "No", 
                "time_frame": "Day 28 (plus or minus 3 days)"
            }, 
            {
                "description": "Intensity of pain will be evaluated on the Huskisson VAS pain scale on which 0 mm indicate 'no pain' and 100 mm indicate 'extreme pain'.", 
                "measure": "Visual Analogue Scale of pain (VAS; 100 mm)", 
                "safety_issue": "No", 
                "time_frame": "Day 90 (plus or minus 3 days)"
            }, 
            {
                "description": "Intensity of pain will be evaluated on the Huskisson VAS pain scale on which 0 mm indicate 'no pain' and 100 mm indicate 'extreme pain'.", 
                "measure": "Visual Analogue Scale of pain (VAS; 100 mm)", 
                "safety_issue": "No", 
                "time_frame": "Day 180 (plus or minus 3 days)"
            }, 
            {
                "description": "Measured by Clinical Global Impression (CGI) 7-point scale, ranking from 'very much improved' to 'very much worse' condition.", 
                "measure": "Patient's and investigator's global evaluation of study-relevant tendon complaints", 
                "safety_issue": "No", 
                "time_frame": "Day 7 (plus or minus 1 day)"
            }, 
            {
                "description": "Measured by Clinical Global Impression (CGI) 7-point scale, ranking from 'very much improved' to 'very much worse' condition.", 
                "measure": "Patient's and investigator's global evaluation of study-relevant tendon complaints", 
                "safety_issue": "No", 
                "time_frame": "Day 28 (plus or minus 3 days)"
            }, 
            {
                "description": "Measured by Clinical Global Impression (CGI) 7-point scale, ranking from 'very much improved' to 'very much worse' condition.", 
                "measure": "Patient's and investigator's global evaluation of study-relevant tendon complaints", 
                "safety_issue": "No", 
                "time_frame": "Day 90 (plus or minus 3 days)"
            }, 
            {
                "description": "Measured by Clinical Global Impression (CGI) 7-point scale, ranking from 'very much improved' to 'very much worse' condition.", 
                "measure": "Patient's and investigator's global evaluation of study-relevant tendon complaints", 
                "safety_issue": "No", 
                "time_frame": "Day 180 (plus or minus 3 days)"
            }, 
            {
                "description": "Redness\nWarmth\nSwelling\nTenderness on palpation\nCrepitus on motion\nAccumulation of tissue fluid\nMeasured by 5-point scale, ranking from 'none' to 'extreme' intensity.", 
                "measure": "Clinical Parameters", 
                "safety_issue": "No", 
                "time_frame": "Day 0"
            }, 
            {
                "description": "Redness\nWarmth\nSwelling\nTenderness on palpation\nCrepitus on motion\nAccumulation of tissue fluid\nMeasured by 5-point scale, ranking from 'none' to 'extreme' intensity.", 
                "measure": "Clinical Parameters", 
                "safety_issue": "No", 
                "time_frame": "Day 7 (plus or minus 1 day)"
            }, 
            {
                "description": "Redness\nWarmth\nSwelling\nTenderness on palpation\nCrepitus on motion\nAccumulation of tissue fluid\nMeasured by 5-point scale, ranking from 'none' to 'extreme' intensity.", 
                "measure": "Clinical Parameters", 
                "safety_issue": "No", 
                "time_frame": "Day 28 (plus or minus 3 days)"
            }, 
            {
                "description": "Redness\nWarmth\nSwelling\nTenderness on palpation\nCrepitus on motion\nAccumulation of tissue fluid\nMeasured by 5-point scale, ranking from 'none' to 'extreme' intensity.", 
                "measure": "Clinical Parameters", 
                "safety_issue": "No", 
                "time_frame": "Day 90 (plus or minus 3 days)"
            }, 
            {
                "description": "Redness\nWarmth\nSwelling\nTenderness on palpation\nCrepitus on motion\nAccumulation of tissue fluid\nMeasured by 5-point scale, ranking from 'none' to 'extreme' intensity.", 
                "measure": "Clinical Parameters", 
                "safety_issue": "No", 
                "time_frame": "Day 180 (plus or minus 3 days)"
            }, 
            {
                "measure": "Frequency of test product-related Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 180"
            }
        ], 
        "source": "TRB Chemedica AG", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "TRB Chemedica AG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}